Thomas, a good e-mail friend from Germany, forwarded me information about a new, possibly revolutionary anti-myeloma Heat Shock Inhibitor this week. Here are some links about this new therapy, PU-H71:
The last three links were provided by my editor at The Myeloma Beacon, Julie Shilane. Thanks for the updates, Thomas and Julie! From Germany to Princeton, New Jersy to Tampa, Florida. Information sure travels far and fast these days, doesn’t it?
But this wasn’t enough for Thomas, who is obsessed (in a good way!) with identifying possible cures for our cancer. He contacted Dr. Gabriela Chiosis, Frederick Adler Chair of molecular Pharmacology&Chemistry and the Department of Medicine at Memorial Sloan-Kettering Cancer Center.
The agent PU-H71 has yet to receive FDA approval to enter Phase 1. we hope
to receive that by early next year, but considering the predictable and
unpredictable delays faced at this stage, I can only estimate such start
date. The phase 1 will be an open label trial.
Best regards, Gabriela
Bottom line: Cure or not, it will be a number of years before we know if the success of PU-H71 translates from test tube to patient. I would ask you to “keep your fingers crossed,” but they would probably cramp-up and fall-off before this science is available in a safe, proven and FDA approved delivery method for multiple myeloma patients.
Still, I get a positive vibe reading stories like this. Frustrating? Sometimes. But for me they provide hope.
Its great to know there are scientists working tirelessly out there, trying to help us.
Feel good and keep smiling! Pat